The HER family and cancer: emerging molecular mechanisms and therapeutic targets
- 31 December 2007
- journal article
- review article
- Published by Elsevier BV in Trends in Molecular Medicine
- Vol. 13 (12), 527-534
- https://doi.org/10.1016/j.molmed.2007.10.002
Abstract
No abstract availableKeywords
This publication has 81 references indexed in Scilit:
- Targeting the function of the HER2 oncogene in human cancer therapeuticsOncogene, 2007
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 2007
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Nature, 2007
- Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell linesBiochemical and Biophysical Research Communications, 2006
- An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor ReceptorCell, 2006
- Phosphotyrosine interactome of the ErbB‐receptor kinase familyMolecular Systems Biology, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003